Alan Tam
Family · San Francisco, CANPI 1154960334
Payments from drug & device makers
Across 202 payments — averaging $22.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$873
- AstraZeneca$609
- Novo Nordisk$476
- Merck$251
- Lilly USA, LLC$233
- Amarin Pharma, Inc.$233
- plus $2K from 15 others
What the payments were for
- Food & beverage$4,454100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 30 | $873 |
| AstraZeneca | 27 | $609 |
| Novo Nordisk | 23 | $476 |
| Merck | 12 | $251 |
| Lilly USA, LLC | 14 | $233 |
| Amarin Pharma, Inc. | 12 | $233 |
| Esperion Therapeutics, Inc. | 9 | $208 |
| Gilead | 8 | $197 |
| AbbVie | 8 | $196 |
| Sunovion Pharmaceuticals Inc. | 13 | $196 |
| Bayer | 7 | $173 |
| Johnson & Johnson | 8 | $172 |
| Astellas Pharma US Inc | 8 | $152 |
| Biohaven Pharmaceutical Holding Company Ltd. | 8 | $131 |
| Boehringer Ingelheim | 6 | $126 |
| Eisai Inc. | 4 | $118 |
| Avanir Pharmaceuticals, Inc. | 1 | $25 |
| Pfizer | 1 | $24 |
| Eyevance Pharmaceuticals LLC | 1 | $23 |
| E.r. Squibb & Sons, L.L.C. | 1 | $20 |
| Scilex Pharmaceuticals Inc. | 1 | $20 |
How this compares
$4,454 in reported general payments places this provider in the 90th percentile of 10,634 family providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 79 | $108,749 |
| EliquisApixaban | 66 | $87,671 |
| JanuviaSitagliptin Phosphate | 45 | $56,243 |
| OzempicSemaglutide | 33 | $33,623 |
| MyrbetriqMirabegron | 46 | $28,304 |
| TrulicityDulaglutide | 21 | $23,670 |
| Atorvastatin Calcium | 340 | $7,247 |
| Rosuvastatin Calcium | 72 | $4,394 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 16 | $4,109 |
| Omeprazole | 123 | $2,896 |
| Gabapentin | 142 | $2,692 |
| Amlodipine Besylate | 288 | $2,676 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 74 | $2,637 |
| Mirtazapine | 88 | $2,459 |
| Tamsulosin Hcl | 79 | $2,322 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $126 | $108,74979 claims |
| PfizerEliquis | $24 | $87,67166 claims |
| MerckJanuvia | $251 | $56,24345 claims |
| Novo NordiskOzempic | $476 | $33,62333 claims |
| Astellas Pharma US IncMyrbetriq | $152 | $28,30446 claims |
| Lilly USA, LLCTrulicity, Humulin N, Insulin Lispro | $233 | $25,34450 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,634 family providers in California.
Other family in San Francisco
- Gabriel SchwartzSan Francisco$166K
- Annika EhrlichSan Francisco$128K
- Monica VolzSan Francisco$96K
- Alicia ChangSan Francisco$45K
- Bethany KinseySan Francisco$33K
- Lori RobertsonChino Hills$475K
- Annette ShonLos Angeles$406K
- Nancy GardettoSan Diego$394K
- Lisa HigginsHanford$311K
- Jennifer TougasBakersfield$302K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.